- What This Exam Actually Is (and Is Not)
- Format, Scoring, and Fee Mechanics
- Eligibility Before You Study
- Reading the Blueprint: Where the Points Are
- High-Yield Domain Breakdowns
- Small Domains That Still Cost You Points
- A Domain-Sequenced Study Calendar
- Using Practice Questions Without Fooling Yourself
- After You Pass: Term and OCC
- Frequently Asked Questions
- The exam is 300 multiple-choice questions over seven hours, administered through AOBIM with AOA certification approval.
- You need a scaled score of at least 500 on a 200-800 scale; 500 is not a raw percentage.
- Hematologic malignancies (15-19%) and Genitourinary tumors (10-14%) are the two heaviest of 17 content areas.
- Exam fee is $800; adding the $240 late surcharge brings the total to $1,040.
What This Exam Actually Is (and Is Not)
Before you buy a single review resource, confirm you are preparing for the right credential. This guide covers the subspecialty certification in Oncology offered by the American Osteopathic Board of Internal Medicine (AOBIM), with certification approval through the American Osteopathic Association (AOA). It is a separate pathway from ABIM Medical Oncology and from any combined hematology-oncology examination.
That distinction matters for preparation. The AOBIM content outline has its own 17 content areas with its own percentage ranges. A candidate who studies from an ABIM-oriented blueprint may over-invest in areas that carry modest weight here and under-invest in others. If you want the background on what the credential is and how it fits into the broader landscape, see our overview of what Oncology certification is and the general Oncology Certification page.
Format, Scoring, and Fee Mechanics
What the exam looks like
The initial written examination contains 300 multiple-choice questions and runs seven hours. That is a long sitting, and endurance is a real variable. Candidates who have only practiced in 50-question blocks often discover that decision quality in the final third of the exam is the weakest part of their performance. Build stamina deliberately, and run at least a few extended sessions before test day.
How scoring works
Passing requires a scaled score of at least 500 on the AOA 200-800 scale. The key point: 500 is not a raw percentage of correct answers. Do not walk out of practice sessions assuming you need a particular percent correct. Scaled scoring exists so that results remain comparable across different exam forms. For a deeper look at how to interpret the threshold, read our guide to the Oncology passing score.
What it costs
| Item | Amount (USD) | Notes |
|---|---|---|
| Initial examination | $800 | Base fee |
| Late surcharge | $240 | Applies if you miss the standard deadline |
| Examination plus late surcharge | $1,040 | Calculated total |
| Optional score audit | $200 | Must be requested within one month of results |
The practical lesson is simple: file on time. The late surcharge adds $240 to an exam that already represents a significant investment. The score audit is optional, and the one-month window means you should decide quickly after results arrive rather than letting it lapse. For the full financial picture, including preparation costs, see our Oncology certification cost breakdown.
Eligibility Before You Study
Do not start a six-month study plan until you know you are eligible to sit. The requirements include:
- AOA board certification in internal medicine
- Two years of an ACGME-accredited or AOA-recognized Oncology or Hematology/Oncology fellowship
- An active medical license
- Ethical standing
- A completed application with program-director verification
A qualifying three-year combined or separate hematology/oncology training route can also support applications for the separate Hematology and Oncology examinations. If your training path is unusual, confirm details with AOBIM directly and review our Oncology requirements guide before you finalize your timeline. Program-director verification in particular can take time to arrange, so start that paperwork early.
Reading the Blueprint: Where the Points Are
The AOBIM outline divides the exam into 17 content areas, each with an official percentage range. These are ranges, not fixed counts, so do not substitute midpoints and treat them as exact. Use them to decide proportional emphasis, not to predict how many questions you will see on a given topic.
| Content Area | Official Range |
|---|---|
| Hematologic malignancies | 15-19% |
| Genitourinary tumors | 10-14% |
| Gastrointestinal tumors | 6-10% |
| Chemotherapy toxicity | 6-10% |
| Breast tumors | 5-9% |
| Supportive care/palliative/ethics | 5-9% |
| Thoracic tumors | 4-8% |
| Paraneoplastic syndromes | 4-8% |
| Gynecologic tumors | 3-7% |
| Pharmacology/cancer biology/cancer genetics | 2-6% |
| Pancreatic/liver cancer | 2-6% |
| Prevention/screening | 2-6% |
| Skin cancer | 1-5% |
| Head and neck cancer | 1-5% |
| Bone/soft tissue/sarcoma | 1-5% |
| Opportunistic infection | 1-4% |
| Cancer trials | 1-3% |
Notice what the distribution tells you. The top two areas alone represent a large share of the exam, and the next four (GI tumors, chemotherapy toxicity, breast tumors, supportive care) form a solid middle tier. A full walkthrough of every area lives in our complete guide to all 17 content areas.
High-Yield Domain Breakdowns
Hematologic Malignancies (15-19%)
The largest single area. Expect questions that require integrating diagnosis, risk stratification, and treatment selection rather than isolated recall.
- Acute and chronic leukemias: presentation, cytogenetic and molecular risk, and treatment logic
- Lymphomas, both Hodgkin and non-Hodgkin, including staging and first-line approach
- Plasma cell disorders and myeloma-related complications
- Myeloproliferative and myelodysplastic disorders
- Transplant considerations and treatment-related complications
Genitourinary Tumors (10-14%)
The second-heaviest area, and one candidates often under-prepare for because prostate, bladder, kidney, and testicular cancers each have distinct management algorithms.
- Prostate cancer: risk grouping, hormonal therapy concepts, and management of advanced disease
- Bladder and urothelial cancer: muscle-invasive versus non-muscle-invasive decisions
- Renal cell carcinoma: staging and systemic therapy concepts
- Testicular germ cell tumors: markers, staging, and the high curability of this group
Chemotherapy Toxicity (6-10%)
This area rewards pattern recognition. Questions often present a patient mid-treatment and ask you to identify the culprit agent or the right intervention.
- Agent-specific toxicities (cardiac, pulmonary, neurologic, renal, hepatic)
- Neutropenia, mucositis, and emetogenic risk
- Recognition and management of acute infusion and hypersensitivity reactions
- Dose-limiting toxicities and when to hold or modify therapy
Because toxicity questions pair naturally with pharmacology, study the agents once and cross-reference them against the disease-specific regimens you encounter in the tumor-type areas.
The middle tier: GI, breast, supportive care
Gastrointestinal tumors (6-10%) and breast tumors (5-9%) are classic board territory: staging, receptor and molecular status, adjuvant versus neoadjuvant logic, and surveillance. Supportive care, palliative care, and ethics (5-9%) is easy to dismiss as soft content, but it frequently produces some of the more approachable questions on the exam if you have practiced the framework for goals-of-care conversations, symptom management, and decision-making capacity.
Small Domains That Still Cost You Points
Candidates often make the same mistake: they pour hours into the top two areas and treat everything else as optional. With 300 questions, the smaller areas collectively matter. Several deserve targeted attention:
- Paraneoplastic syndromes (4-8%): Memorize the tumor-to-syndrome associations. These are fertile ground for recall-based questions and reward compact, repeated review.
- Thoracic tumors (4-8%): Lung cancer subtypes, molecular drivers, and staging-driven treatment pathways.
- Gynecologic tumors (3-7%): Ovarian, endometrial, and cervical cancers, with attention to genetic syndromes.
- Pharmacology, cancer biology, and cancer genetics (2-6%): Mechanisms of action and hereditary cancer syndromes, which also support questions in other areas.
- Pancreatic and liver cancer (2-6%): Resectability concepts, risk factors, and systemic therapy basics.
- Prevention and screening (2-6%): Guideline-based screening logic and risk-reduction strategies.
- Skin cancer, head and neck cancer, and bone/soft tissue/sarcoma (each 1-5%): Lower weight, but a handful of questions each.
- Opportunistic infection (1-4%) and cancer trials (1-3%): Small, but the infection content overlaps with neutropenic and immunosuppressed patients, and trial-design vocabulary is quick to learn.
Key Takeaway
Use the small areas as efficiency wins. Paraneoplastic syndromes, cancer trials, and opportunistic infection are compact topics you can master in a short block, converting limited study time into reliable points.
A Domain-Sequenced Study Calendar
Rather than a generic weekly template, sequence your preparation by blueprint weight and by how topics reinforce each other. Here is one way to structure a roughly eight-week plan; stretch it if your clinical schedule demands.
Hematologic malignancies
- Work through leukemias, lymphomas, myeloma, and myeloid disorders
- Start a running list of recurring regimens and their toxicities
Genitourinary tumors
- Prostate, bladder, kidney, and testicular management algorithms
- Pair with pharmacology of hormonal and targeted agents
GI, pancreatic/liver, and breast
- Staging, molecular markers, and adjuvant versus neoadjuvant decisions
Chemotherapy toxicity and pharmacology
- Consolidate agent-specific toxicities now that you have met most regimens
- Review cancer biology and genetics
Thoracic, gynecologic, and the small tumor areas
- Lung, gynecologic, skin, head and neck, and sarcoma
Paraneoplastic, supportive care, prevention, infection, trials
- Drill syndrome associations and goals-of-care frameworks
Mixed review and endurance
- Long, timed sessions that mimic the seven-hour format
- Revisit weak areas identified by practice results
The logic: hematologic malignancies come first because of their weight and because their regimens feed directly into the toxicity week. Toxicity sits mid-plan so you can connect it to drugs you have already seen. The small areas come late, when short, high-recall review is most efficient.
Using Practice Questions Without Fooling Yourself
Practice questions are most valuable when they are mapped to the actual AOBIM Oncology outline. Look for original questions with explanations that tie back to the content areas above, rather than recycled material built around a different board's blueprint. Our Oncology practice test site is built around that principle, and you can start with the practice questions there to benchmark where you stand.
- Tag every miss by content area. After a block, note which of the 17 areas the question belonged to. Patterns appear quickly.
- Read explanations for questions you got right. A lucky guess is a gap in disguise.
- Do not translate practice percentages into a prediction. Because the real passing standard is a scaled score of at least 500, a practice-test percentage is only a rough directional signal.
- Simulate the long format. Complete at least a couple of extended sessions to train focus across hours, not minutes.
If you are weighing how demanding the exam is relative to your preparation, our piece on how hard the Oncology exam is and our look at the Oncology pass rate offer useful context. For a fast pre-exam refresher, the Oncology cheat sheet condenses key facts into one page. When you are ready to test yourself under realistic conditions, head to the main practice test hub.
After You Pass: Term and OCC
Certification carries a ten-year term, conditional on Osteopathic Continuous Certification (OCC). Knowing the maintenance picture now helps you plan your career, not just your exam date.
For the 2025-2027 cycle, time-limited diplomates need:
- 60 CME credits over three years, including 15 Category 1 and/or Category 1-A credits
- One quality-improvement activity attestation per three-year cycle
- Active licensure
Oncology remains on the remotely proctored subspecialty OCC examination route, offered annually in August. Diplomates may begin that examination two years before certificate expiration, and a successful early renewal extends from the existing certificate's expiration date, so testing early does not cost you time. Keep this separate in your mind from the primary internal-medicine longitudinal assessment, which is a different component of OCC.
Frequently Asked Questions
The initial written examination contains 300 multiple-choice questions and lasts seven hours.
A scaled score of at least 500 on the AOA 200-800 scale. This is not a raw percentage of correct answers, so avoid converting it into a simple percent-correct target.
The initial examination fee is $800. A late surcharge of $240 brings the total to $1,040, and an optional score audit costs $200 and must be requested within one month of results.
Hematologic malignancies is the largest at 15-19%, followed by Genitourinary tumors at 10-14%. These are official ranges, so treat them as guides to relative emphasis rather than exact question counts.
No. This is the AOBIM subspecialty certification in Oncology, with certification approval through the AOA. It uses its own 17-area outline and its own OCC pathway, so you should not prepare from an ABIM blueprint.
Preparing for this exam comes down to three things: knowing the AOBIM blueprint, sequencing your study around its heaviest areas, and building the stamina to perform across a seven-hour sitting. For a broader look at timing and logistics, review the Oncology exam dates guide, and when you are ready to practice, start with the questions at Oncology Exam Prep.